Daratumumab
Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1) . Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition[1][2].
Product Specifications
CAS Number
945721-28-8
Product Name Alternative
Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414
UNSPSC
12352203
Target
ADC Antibody; CD38
Type
Inhibitory Antibodies
Related Pathways
Antibody-drug Conjugate/ADC Related; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/daratumumab.html
Purity
99.10
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
[Daratumumab]
Molecular Weight
(145.26 kDa)
References & Citations
[1]Ghose J, Viola D, et al. Daratumumab induces CD38 internalization and impairs myeloma cell adhesion. Oncoimmunology. 2018;7 (10) :e1486948. Published 2018 Jul 23.|[2]de Weers M, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186 (3) :1840-1848.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
